What it's for (Indications)
- Ertapenem, marketed under the brand name Invanz, is a broad-spectrum carbapenem antibiotic indicated for the treatment of moderate to severe infections caused by susceptible strains of microorganisms.
- Its approved indications include complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, complicated urinary tract infections (cUTI), and acute pelvic infections (including postpartum endomyometritis, septic abortion, and post-surgical gynecologic infections).
- It is also approved for the prophylaxis of surgical site infection following elective colorectal surgery.
- The effectiveness of ertapenem in these conditions relies on its robust activity against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria, making it a valuable agent for empiric therapy in critically ill patients or those with polymicrobial infections where specific pathogens are not yet identified.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adult patients and adolescents (13 years of age and older), the recommended dosage of ertapenem is 1 gram (1000 mg) administered once daily, either intravenously (IV) over a period of 30 minutes or intramuscularly (IM). The duration of treatment is dependent on the type and severity of the infection, the patient's clinical response, and the specific pathogens identified, typically ranging from 3 to 14 days. For pediatric patients aged 3 months to 12 years, the recommended dosage is 15 mg/kg administered intravenously twice daily, up to a maximum daily dose of 1 gram. Dosage adjustment is critical for patients with impaired renal function; for those with creatinine clearance (CrCl) >30 mL/min/1.73 m², no adjustment is needed, but for CrCl ≤30 mL/min/1.73 m² (including hemodialysis patients), the dose should be reduced to 500 mg once daily. Ertapenem should be given after hemodialysis sessions on dialysis days. |
Safety & Warnings
Common Side Effects
- Common adverse effects associated with ertapenem therapy include gastrointestinal disturbances such as diarrhea, nausea, and vomiting.
- Other frequently reported side effects involve headache, rash, and local reactions at the injection site (e.
- g.
- , pain, inflammation, erythema).
- More serious adverse events, though less common, warrant careful monitoring.
- These can include severe hypersensitivity reactions, ranging from rash to life-threatening anaphylaxis, and potentially severe dermatological reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis.
- Central Nervous System (CNS) effects, particularly seizures, confusion, and altered mental status, have been reported, especially in patients with pre-existing CNS disorders or compromised renal function.
- Additionally, ertapenem can cause Clostridium difficile-associated diarrhea (CDAD), ranging from mild to severe and potentially fatal colitis.
- Hematological abnormalities (e.
- g.
- , thrombocytopenia, neutropenia) and hepatic enzyme elevations may also occur, necessitating regular laboratory surveillance during prolonged treatment.
Serious Warnings
- Black Box Warning: While ertapenem (Invanz) does not carry a formal FDA Black Box Warning, clinicians must be acutely aware of several critical safety concerns that necessitate meticulous patient evaluation and ongoing surveillance during therapy. These serious warnings emphasize the potential for severe hypersensitivity reactions, including anaphylaxis, which can be life-threatening and occur even in individuals without a prior history of beta-lactam allergy, though cross-reactivity with penicillins and cephalosporins is a recognized risk factor. Furthermore, ertapenem is associated with significant Central Nervous System (CNS) adverse effects, predominantly seizures, but also including confusion, hallucinations, and altered mental status. This risk is notably elevated in patients with a history of CNS disorders or compromised renal function, where drug accumulation can lead to increased neurotoxicity. The development of Clostridium difficile-associated diarrhea (CDAD) is another grave concern, ranging from mild diarrhea to severe, potentially fatal colitis, which can manifest during or even several months post-treatment. Appropriate renal dose adjustments are imperative for patients with impaired kidney function to mitigate the risk of drug accumulation and associated CNS toxicity.
- Ertapenem carries several important warnings that healthcare professionals must consider to ensure patient safety.
- Patients with a history of hypersensitivity to beta-lactam antibiotics (e.
- g.
- , penicillins, cephalosporins) are at an increased risk for serious and potentially fatal anaphylactic reactions to ertapenem due to potential cross-reactivity.
- Careful inquiry into prior allergic reactions is essential before initiating therapy.
- Furthermore, ertapenem has been associated with Central Nervous System (CNS) adverse effects, including seizures, confusion, and encephalopathy, particularly in patients with a history of CNS disorders (e.
- g.
- , seizure disorder, brain lesions) or those with impaired renal function, where drug accumulation can increase neurotoxicity.
- Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including ertapenem, and can range in severity from mild diarrhea to fatal colitis.
- It is crucial to consider CDAD in patients presenting with diarrhea during or after antibiotic use.
- Superinfection with non-susceptible organisms can also occur, necessitating careful monitoring for new infections.
- Dosage adjustments are mandatory in patients with renal impairment to mitigate the risk of adverse effects.
How it Works (Mechanism of Action)
Ertapenem is a bactericidal carbapenem antibiotic that exerts its effect by inhibiting bacterial cell wall synthesis. It achieves this by covalently binding to and inactivating several penicillin-binding proteins (PBPs) located on the bacterial cell membrane, which are essential enzymes involved in the cross-linking of peptidoglycan, a vital component of the bacterial cell wall. By disrupting the peptidoglycan synthesis, ertapenem weakens the cell wall integrity, leading to osmotic lysis and ultimately bacterial cell death. Ertapenem exhibits a broad spectrum of activity against many Gram-positive and Gram-negative aerobic and anaerobic bacteria, including many strains resistant to other beta-lactam antibiotics. Its stability against hydrolysis by a wide range of beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), contributes to its efficacy against resistant pathogens, although it is not active against metallo-beta-lactamases (MBLs).
Commercial Brands (Alternatives)
No other brands found for this formula.